Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Authors:

Abstract
Patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase.
Funding Information
  • Seattle Genetics

This publication has 25 references indexed in Scilit: